TABLE 2. Vaccine product administered as booster or additional primary dose* in respect to that used in primary series for booster or additional primary dose recipients aged ≥65 years, by primary series vaccine product — United States, August 13–November 19, 2021.
| Characteristic | No. (column %), by primary series vaccine product |
|||
|---|---|---|---|---|
| Total | Pfizer-BioNTech | Moderna | Janssen (Johnson & Johnson) | |
|
No. of booster or additional primary dose recipients
|
18,745,803
|
9,925,719 |
8,425,884 |
369,260 |
|
Type of booster or additional primary dose
| ||||
| Homologous dose |
17,957,427 (95.8)
|
9,744,109 (98.2) |
8,071,200 (95.8) |
142,118 (38.5) |
| Heterologous dose | 748,099 (4.0) | 168,336 (1.7) | 352,684 (4.2) | 227,079 (61.5) |
* The type of vaccine product administered for the booster or additional primary dose in respect to that used in the primary series was unable to be determined for 40,277 (0.2%) persons. These persons had an unspecified U.S.-authorized or approved mRNA COVID-19 vaccine product administered as either the primary series or as a booster or additional primary dose.